Early access
Sign in
Not yet taking people in Hong KongNo phase

Following blood changes over time to spot common long-term diseases earlier

Collects blood samples and health data from adults to study early disease changes.

Key facts

Who runs it
The University of Hong Kong
Where
Hong Kong, Hong KongSee the site
Trial code
Registry title
Global Longitudinal Health Monitoring and Blood Sample Collection Study to Promote Early-stage Disease Detection and Personalized/Precision Care Using Innovative Research Platforms
Status
Not yet recruiting
People taking part
15,000 people, planned
Started
1 May 2026
Expected to end
29 May 2048
Type of study
Observational, 2 groups
Record updated
6 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 40 to 70 who are healthy. Some have low risk and some have high risk of future non-communicable diseases such as heart disease, diabetes, COPD or cancer.

Age
40 years to 70 years
Sex
Men and women can join.
Disease stage
Healthy, with no acute or chronic disease. Mild problems that need no regular drug treatment are allowed. A low-risk group and a high-risk group are included.
Earlier treatment
Low-risk group: no blood pressure medicine ever, no cholesterol-lowering treatment, no regular prescription drug therapy. High-risk group: only medicines for controlled high blood pressure or cholesterol are allowed.
Biomarker or test result
Body mass index (BMI) 18.5 - 35.0 kg/m^2. Low-risk group: total cholesterol < 5.2 mmol/L (<200 mg/dL), non-smoker or less than 5 pack-years of smoking. High-risk group: at least 2 of 3 risk factors (treated high blood pressure, treated high cholesterol, smoking of more than 20 pack-years and/or a close relative with lung cancer).

Main reasons for not taking part

  • Pregnancy at the first visit (self-reported)
  • History of the target non-communicable diseases or other significant health conditions
  • Past HIV, HBV, HCV or HEV infection
  • Vulnerable participants
  • Foreseeable lack of compliance

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Signed informed consent form (ICF) of the study
  • Male or female participants
  • Age at Visit 1: 40 years - 70 years
  • For Low-risk Arm: Assessed as healthy (free of acute or chronic disease) with no cardiovascular risk conditions listed in Inclusion criteria 5. Participants may have mild disorders that do not require regular therapeutic (pharmacological) intervention; For High-risk Arm: Assessed as healthy (free of acute or chronic diseases) with cardiovascular risk conditions listed in Inclusion criteria 5. Participant may have mild disorders that do not require regular therapeutic (pharmacological) intervention
  • For Low-risk Arm: Has low risk to contract an NCD in the upcoming years, according to the following criteria: a) Non-hypertensive person according to criteria of the relevant national guideline, who never received antihypertensive medication; b) Total cholesterol: < 5.2 mmol/L (<200 mg/dL) with no history of lipid-lowering (e.g., statin) treatment; c) Non smoker or with no significant smoking history (<5 pack-years); For High-risk Arm: Has high risk to contract an NCD in the upcoming years, confirmed by the presence of at least 2 out of the following 3 criteria (a, b, c): a) Medically controlled hypertension: participants with diagnosed hypertension receiving antihypertensive medication ; b) Medically controlled dyslipidemia or hypercholesterolemia: participants with diagnosed dyslipidemia or hypercholesterolemia receiving lipid-lowering medication; c) Significant smoking history (tobacco exposure of >20 pack-years) and/or 1st degree family member with history of lung cancer
  • BMI: 18.5 - 35.0 kg/m\^2
  • Willingness to fill in the study questionnaire
  • Willingness to participate in future visits and medical investigations as defined per protocol
  • Willingness to be followed-up on disease outcome through data linkage to the participant's health-related records

Who cannot take part

  • For low-risk arm: Past medical history (PMH) of target NCDs, any other significant health conditions, clinical symptoms, abnormalities of blood parameters or medical tests suggesting the presence of abnormal health conditions at Visit 1. Any condition that is inadequately controlled. The sponsor should be contacted for advice in case of any uncertainties; For high-risk arm: Except for the conditions mentioned under inclusion criteria (point 5a and b), participants with PMH of target NCDs, any other health conditions, clinical symptoms, abnormalities of blood parameters or medical tests suggesting the presence of abnormal health conditions at Visit 1 are excluded from the study. Any condition that is inadequately controlled. Sponsor should be contacted for advice in case of any uncertainties
  • For low-risk arm: Any chronic, systemic drug therapy at Visit 1 (prescription); For high-risk arm: Any chronic, systemic drug therapy at Visit 1 except for conditions mentioned under Inclusion criteria (point 5a and b)
  • History of HIV, HBV, HCV or HEV infection at Visit 1
  • Pregnancy at Visit 1 (self-reported, no test required)
  • Vulnerable participants
  • Foreseeable lack of compliance

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 40 and 70 years old?

Where in Hong Kong

  • School of Public Health, The University of Hong KongHong Kong, Hong KongContact: Teresa HC SoNot yet recruiting

About the trial

What the trial wants to find out

The investigators propose a prospective, longitudinal, observational study to improve health assessment by analyzing blood plasma molecular patterns in each individual over time using artificial intelligence (AI) to identify key measurements for early detection of NCDs. It will develop personalized reference ranges and screening methods, laying the foundation for population-based early detection. This study focus on collecting health data and biospecimen samples to understand early molecular changes linked to disease.

The 2 groups in the trial

  • Low-risk arm

    a cohort of 7,500 participants with the absence of modifiable cardiovascular risk factors, who are at low risk of contracting selected NCDs

  • High-risk arm

    a cohort of 7,500 participants with the presence of cardiovascular risk factors, who are at high risk of contracting selected NCDs

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Global Longitudinal Health Monitoring and Blood Sample Collection Study to Promote Early-stage Disease Detection and Personalized/Precision Care Using Innovative Research Platforms
Plain-language title
Following blood changes over time to spot common long-term diseases earlierGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07570667, who can take part
Record updated
6 May 2026